BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. [PMID: 28612180 DOI: 10.1007/s40259-017-0231-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 32.8] [Reference Citation Analysis]
Number Citing Articles
1 Johar A, Thevarajah S, Heng A, Chan LC, Ch'ng CC, Mohd Safdar NA, Muniandy P, Taib T, Tan WC, Tey KE. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatol Res Pract 2019;2019:8923168. [PMID: 31214257 DOI: 10.1155/2019/8923168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol 2020;17:387-401. [PMID: 32203286 DOI: 10.1038/s41569-020-0352-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 35.0] [Reference Citation Analysis]
3 Michielsens CAJ, van Muijen ME, Verhoef LM, van den Reek JMPA, de Jong EMGJ. Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. Drugs 2021;81:349-66. [PMID: 33453052 DOI: 10.1007/s40265-020-01448-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yang J, Lickliter JD, Hillson JL, Means GD, Sanderson RJ, Carley K, Tercero A, Manjarrez KL, Wiley JR, Peng SL. First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects. Clin Transl Sci 2021;14:1314-26. [PMID: 33503289 DOI: 10.1111/cts.12983] [Reference Citation Analysis]
5 Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
6 Skrabl-baumgartner A, Seidel G, Langner-wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child 2019;104:246-50. [DOI: 10.1136/archdischild-2018-315060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
7 Vainshtein I, Sun B, Roskos LK, Liang M. A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains. Journal of Immunological Methods 2020;477:112688. [DOI: 10.1016/j.jim.2019.112688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Tesar T, Golias P, Kobliskova Z, Wawruch M, Kawalec P, Inotai A. Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Front Public Health 2020;8:431. [PMID: 32974261 DOI: 10.3389/fpubh.2020.00431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Saito Y, Hayashi S, Gonmori T, Hamasaki Y, Igawa K. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease. Int J Dermatol 2020;59:e159-60. [PMID: 32034760 DOI: 10.1111/ijd.14809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther 2022;24:61. [PMID: 35232462 DOI: 10.1186/s13075-022-02744-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. J Eur Acad Dermatol Venereol 2021;35:329-37. [PMID: 33030275 DOI: 10.1111/jdv.16980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Rosenbaum JT, Friedman M. Seasoning to Perfection: How to Optimize Anti-TNF Therapy. Ocul Immunol Inflamm 2021;:1-2. [PMID: 34424794 DOI: 10.1080/09273948.2021.1964032] [Reference Citation Analysis]
13 Statie RC, Florescu DN, Gheonea DI, Ciurea T. Rare Complication During Anti-TNF-α Treatment in a Patient with Crohn's Disease: A Case Report and Review of the Literature. Curr Health Sci J 2021;47:132-8. [PMID: 34211761 DOI: 10.12865/CHSJ.47.01.22] [Reference Citation Analysis]
14 Schlesinger N, Padnick-Silver L, LaMoreaux B. Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. BioDrugs 2022. [PMID: 35316517 DOI: 10.1007/s40259-022-00517-x] [Reference Citation Analysis]
15 Gress K, Bass JA, Funk RS, Morrow RP, Hasenkamp R, Shakhnovich V. Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease. Front Immunol 2020;11:1148. [PMID: 32582213 DOI: 10.3389/fimmu.2020.01148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Parrish RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 2021;12:293-301. [DOI: 10.3390/gastroent12030026] [Reference Citation Analysis]
17 Emery P, Suh CH, Weinblatt ME, Smolen JS, Keystone EC, Genovese M, Vencovsky J, Kay J, Hong E, Baek Y, Ghil J. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. Scand J Rheumatol 2020;49:361-70. [PMID: 32468892 DOI: 10.1080/03009742.2020.1732458] [Reference Citation Analysis]
18 Mojtahed Poor S, Ulshöfer T, Gabriel LA, Henke M, Köhm M, Behrens F, Geisslinger G, Parnham MJ, Burkhardt H, Schiffmann S. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. Clin Exp Immunol 2019;196:259-75. [PMID: 30656642 DOI: 10.1111/cei.13261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Germovsek E, Cheng M, Giragossian C. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. MAbs 2021;13:1964935. [PMID: 34530672 DOI: 10.1080/19420862.2021.1964935] [Reference Citation Analysis]
20 Mora JR, Wong R, Shaikh M, Askelson M. Analysis of the Immunogenicity from Abatacept-Treated Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials. ACR Open Rheumatol 2021. [PMID: 34792858 DOI: 10.1002/acr2.11375] [Reference Citation Analysis]
21 Akdogan N, Dogan S, Bostan E, Gulseren D, Yalici-Armagan B, Elcin G, Evans SE, Karaduman A, Atakan N. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis. Expert Rev Clin Pharmacol 2021;:1-7. [PMID: 34519227 DOI: 10.1080/17512433.2021.1979394] [Reference Citation Analysis]
22 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
23 Martín-lópez M, Carmona L, Balsa A, Calvo-alén J, Sanmartí R, Tornero J, Rosas J. Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int 2018;38:975-83. [DOI: 10.1007/s00296-018-4022-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
24 Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Naučno-praktičeskaâ revmatologiâ 2019;57:8-16. [DOI: 10.14412/1995-4484-2019-8-16] [Cited by in Crossref: 27] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
25 Pedersen ME, Østergaard J, Glintborg B, Hetland ML, Jensen H. Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis. Sci Rep 2022;12:4670. [PMID: 35304547 DOI: 10.1038/s41598-022-08682-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kim H, Alten R, Cummings F, Danese S, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 2021;13:1868078. [PMID: 33557682 DOI: 10.1080/19420862.2020.1868078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Nasonov EL, Lila AM. [Rheumatoid arthritis: achievements and unresolved issues]. Ter Arkh 2019;91:4-7. [PMID: 32598670 DOI: 10.26442/00403660.2019.05.000259] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Owczarczyk-Saczonek A, Owczarek W, Osmola-Mańkowska A, Adamski Z, Placek W, Rakowska A. Secondary failure of TNF-α inhibitors in clinical practice. Dermatol Ther 2019;32:e12760. [PMID: 30288872 DOI: 10.1111/dth.12760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
30 Michelsen B, Berget KT, Kavanaugh A, Haugeberg G. Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. Rheumatol Ther 2022. [PMID: 35594016 DOI: 10.1007/s40744-022-00464-7] [Reference Citation Analysis]
31 Mauro VP. Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations. BioDrugs 2018;32:69-81. [PMID: 29392566 DOI: 10.1007/s40259-018-0261-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
32 Lagassé HAD, Hengel H, Golding B, Sauna ZE. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity. AAPS J 2019;21. [DOI: 10.1208/s12248-019-0336-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies? Drugs R D 2021;21:341-50. [PMID: 34106430 DOI: 10.1007/s40268-021-00349-0] [Reference Citation Analysis]
34 Markota Čagalj A, Marinović B, Bukvić Mokos Z. New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int J Mol Sci 2022;23:3753. [PMID: 35409118 DOI: 10.3390/ijms23073753] [Reference Citation Analysis]
35 Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. Br J Clin Pharmacol 2019;85:2264-79. [PMID: 31315147 DOI: 10.1111/bcp.14062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Lin CT, Huang WN, Tsai WC, Chen JP, Hung WT, Hsieh TY, Chen HH, Hsieh CW, Lai KL, Tang KT, Tseng CW, Chen DY, Chen YH, Chen YM. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry. PLoS One 2021;16:e0250877. [PMID: 33930048 DOI: 10.1371/journal.pone.0250877] [Reference Citation Analysis]
37 Boehncke W, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. Expert Review of Clinical Immunology 2018;14:513-23. [DOI: 10.1080/1744666x.2018.1468753] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
38 Chen PK, Lan JL, Chen YM, Chen HH, Chang SH, Chung CM, Rutt NH, Tan TM, Mamat RNR, Anuar ND, Blackburn JM, Chen DY. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA. J Immunol Res 2021;2021:6656121. [PMID: 33763493 DOI: 10.1155/2021/6656121] [Reference Citation Analysis]
39 Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, Cassarà E, Kaloudi O, Cantini F. Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. Ther Clin Risk Manag 2018;14:2097-111. [PMID: 30498353 DOI: 10.2147/TCRM.S175772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Pitzalis C, Choy EHS, Buch MH. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat Rev Rheumatol 2020;16:590-9. [PMID: 32887976 DOI: 10.1038/s41584-020-0491-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Doevendans E, Schellekens H. Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. Antibodies (Basel) 2019;8:E21. [PMID: 31544827 DOI: 10.3390/antib8010021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
42 Tanaka Y, Matsubara T, Hashizume K, Amano N, Takeuchi T. Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Mod Rheumatol 2021:roab029. [PMID: 34897499 DOI: 10.1093/mr/roab029] [Reference Citation Analysis]
43 Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis 2020;14:23-32. [PMID: 31158271 DOI: 10.1093/ecco-jcc/jjz110] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 24.5] [Reference Citation Analysis]
44 Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther 2019;19:1031-43. [PMID: 30574813 DOI: 10.1080/14712598.2019.1561851] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci 2020;4:547-55. [PMID: 33948231 DOI: 10.1017/cts.2020.493] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Mkinsi O, Lefkir-tafiani S, Srairi HS, Kochbati S, El Dershaby YM, El Azhari MM, Midjek SA, Ladjouze-rezig A. Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. TORJ 2019;13:72-84. [DOI: 10.2174/1874312901913010072] [Reference Citation Analysis]
47 Prodeus A, Sparkes A, Fischer NW, Cydzik M, Huang E, Khatri I, Young A, Woo L, Chow CW, Gorczynski R, Gariépy J. A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo. Mol Ther Nucleic Acids 2018;12:350-8. [PMID: 30195773 DOI: 10.1016/j.omtn.2018.05.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Honma M, Hayashi K. Psoriasis: Recent progress in molecular‐targeted therapies. J Dermatol 2021;48:761-77. [DOI: 10.1111/1346-8138.15727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
49 Zhang X, Mei D, Wang H, Yu Q, Hong Z, Xu L, Ge J, Han L, Shu J, Liang F, Cai X, Zhu Y, Zhang F, Wang Q, Tai Y, Wang H, Zhang L, Wei W. hIgDFc-Ig inhibits B cell function by regulating the BCR-Syk-Btk-NF-κB signalling pathway in mice with collagen-induced arthritis. Pharmacol Res 2021;173:105873. [PMID: 34500060 DOI: 10.1016/j.phrs.2021.105873] [Reference Citation Analysis]
50 Rodríguez S, Muñoz A, Bustos RH, Jaimes D. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines 2020;8:E303. [PMID: 32842558 DOI: 10.3390/biomedicines8090303] [Reference Citation Analysis]
51 Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, Zhang Z, Barcellona C, Maes P, Fiorillo L. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. Journal of the American Academy of Dermatology 2020;82:389-97. [DOI: 10.1016/j.jaad.2019.08.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
52 Masui S, Yonezawa A, Izawa K, Hayakari M, Asakura K, Taniguchi R, Isa M, Shibata H, Yasumi T, Nishikomori R, Takita J, Matsubara K. Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report. J Pharm Health Care Sci 2019;5:9. [PMID: 31073411 DOI: 10.1186/s40780-019-0136-4] [Reference Citation Analysis]
53 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Bqain M, Efimov A, Baker D, Kang AS. Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review. Hum Antibodies 2021. [PMID: 34151784 DOI: 10.3233/HAB-210449] [Reference Citation Analysis]
55 Frazier KS. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies. Toxicol Pathol 2022;:1926233221100414. [PMID: 35608030 DOI: 10.1177/01926233221100414] [Reference Citation Analysis]
56 Gelfand JM. Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis. J Neurol Neurosurg Psychiatry 2021:jnnp-2021-326267. [PMID: 33785576 DOI: 10.1136/jnnp-2021-326267] [Reference Citation Analysis]
57 Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. Blood Adv 2019;3:2668-78. [PMID: 31506285 DOI: 10.1182/bloodadvances.2019000338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
58 Eser A, Reinisch W, Schreiber S, Ahmad T, Boulos S, Mould DR. Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. J Clin Pharmacol 2021;61:224-33. [PMID: 32905628 DOI: 10.1002/jcph.1732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Alten R, Markland C, Boyce M, Kawakami K, Muniz R, Genovese MC. Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. Int J Rheum Dis 2020;23:1514-25. [PMID: 32852139 DOI: 10.1111/1756-185X.13951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Spencer EA, Kinnucan J, Wang J, Dubinsky MC. Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers. Crohn's & Colitis 360 2020;2:otaa022. [DOI: 10.1093/crocol/otaa022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P; ABIRISK consortium. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Med 2020;17:e1003348. [PMID: 33125391 DOI: 10.1371/journal.pmed.1003348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Waldron JL, Schworer SA, Kwan M. Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clin Rev Allergy Immunol 2021. [PMID: 34319562 DOI: 10.1007/s12016-021-08879-w] [Reference Citation Analysis]
63 Sun C, Xia J. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis. Minerva Med 2020;111:254-65. [PMID: 32166932 DOI: 10.23736/S0026-4806.20.06460-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 van der Kraaij G, Busard C, van den Reek J, Menting S, Musters A, Hutten B, de Rie M, Ouwerkerk W, van Bezooijen J, Prens E, Rispens T, de Vries A, de Jong E, de Kort W, Lambert J, van Doorn M, Spuls P. Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial. Journal of Investigative Dermatology 2022. [DOI: 10.1016/j.jid.2022.01.033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tornero-Molina J, Alperi-López M, Castellví I, de Agustín-de Oro JJ, Escudero A, García-Vicuña R, González-Gay MÁ, Hidalgo C, Rubio E, Sanmartí R, Casamira N, Calvo-Alén J. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed) 2020:S1699-258X(20)30200-X. [PMID: 33041228 DOI: 10.1016/j.reuma.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mayrhofer P, Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum Antibodies 2019;27:37-51. [PMID: 30103312 DOI: 10.3233/HAB-180347] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
67 Hutto SK, Kyle K, Cavanagh JJ, Reda H, Venna N. Adalimumab for CNS sarcoidosis: single-center experience and literature review. J Neurol 2021. [PMID: 34487233 DOI: 10.1007/s00415-021-10793-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Benucci M, Grossi V, Manfredi M, Damiani A, Infantino M, Moscato P, Cinquanta L, Gremese E, Tolusso B, Petricca L, Fedele AL, Alivernini S, Atzeni F, Minisola G, Verna R. Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Ann Lab Med 2020;40:101-13. [PMID: 31650726 DOI: 10.3343/alm.2020.40.2.101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
69 Faustini F, Dunn N, Kharlamova N, Ryner M, Bruchfeld A, Malmström V, Fogdell-Hahn A, Gunnarsson I. First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. Arthritis Res Ther 2021;23:211. [PMID: 34389040 DOI: 10.1186/s13075-021-02589-6] [Reference Citation Analysis]
70 Emerson AE, Slaby EM, Hiremath SC, Weaver JD. Biomaterial-based approaches to engineering immune tolerance. Biomater Sci 2020;8:7014-32. [PMID: 33179649 DOI: 10.1039/d0bm01171a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kearney N, McKenna K. Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis - does therapeutic drug monitoring have a place in routine clinical practice? J Dermatolog Treat 2021;:1-6. [PMID: 33656955 DOI: 10.1080/09546634.2021.1898526] [Reference Citation Analysis]
72 Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33615953 DOI: 10.1080/14737167.2021.1880324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg JE, Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sundy JS, Tanaka Y. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Mod Rheumatol 2021;:1-16. [PMID: 33274687 DOI: 10.1080/14397595.2020.1859675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). J Rheumatol 2021;48:767-74. [PMID: 32934137 DOI: 10.3899/jrheum.200460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
75 Rosas J, Martín-López M, Otón T, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Carmona L. Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis. Reumatol Clin (Engl Ed) 2020;16:378-85. [PMID: 30385295 DOI: 10.1016/j.reuma.2018.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Wang Q, Oryoji D, Mitoma H, Kimoto Y, Koyanagi M, Yokoyama K, Ayano M, Akahoshi M, Arinobu Y, Niiro H, Akashi K, Horiuchi T. Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents. Front Immunol 2020;11:2042. [PMID: 32922407 DOI: 10.3389/fimmu.2020.02042] [Reference Citation Analysis]
77 Ogata A, Kato Y, Higa S, Maeda K. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 2019;16:639-48. [DOI: 10.1080/17425247.2019.1618828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
78 Yonezawa A. Therapeutic Drug Monitoring of Antibody Drugs. Biol Pharm Bull 2022;45:843-6. [PMID: 35786591 DOI: 10.1248/bpb.b22-00006] [Reference Citation Analysis]
79 Spindeldreher S, Karle A, Correia E, Tenon M, Gottlieb S, Huber T, Maillere B, Kolbinger F. T cell epitope mapping of secukinumab and ixekizumab in healthy donors. MAbs 2020;12:1707418. [PMID: 31924123 DOI: 10.1080/19420862.2019.1707418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
80 Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Świerkot J, Więsik-Szewczyk E, Feldman J. Biosimilar switching - current state of knowledge. Reumatologia 2018;56:234-42. [PMID: 30237628 DOI: 10.5114/reum.2018.77975] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
81 Strand V, Gonçalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. BioDrugs 2020;34:27-37. [PMID: 31721107 DOI: 10.1007/s40259-019-00394-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
82 Abdullah I, Alhendi G, Alhadab A, Alasfour H, Shehab M. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725512. [PMID: 34660635 DOI: 10.3389/fmed.2021.725512] [Reference Citation Analysis]
83 Lee S, Lee H, Kim E. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis. BioDrugs 2019;33:469-83. [PMID: 31446557 DOI: 10.1007/s40259-019-00376-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
84 De Keyser E, Busard CI, Lanssens S, Meuleman L, Hutten BA, Costanzo A, van den Reek JM, Zweegers J, Lambert J, Spuls PI. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. Ther Drug Monit 2019;41:634-9. [PMID: 31107404 DOI: 10.1097/FTD.0000000000000646] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
85 Hansel K, Bianchi L, Tramontana M, Balato A, Scala E, Brozzi J, Stingeni L. Immediate local and systemic hypersensitivity due to etanercept and adalimumab. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:726-7. [DOI: 10.1016/j.jaip.2018.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
86 Deodhar A, Gladman DD, Mcinnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J, Shete A, Bruin G. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. J Rheumatol 2020;47:539-47. [DOI: 10.3899/jrheum.190116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
87 Bandyopadhyay D, Judson MA. Emerging and potential treatment options for sarcoidosis. Expert Opinion on Orphan Drugs 2017;6:17-33. [DOI: 10.1080/21678707.2018.1411260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
88 Sasson SC, Wilkins LE, Watson RA, Jolly C, Brain O, Klenerman P, Olsson-Brown A, Fairfax BP. Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Sci Rep 2021;11:19253. [PMID: 34584157 DOI: 10.1038/s41598-021-98700-7] [Reference Citation Analysis]
89 Klein A. Biologikabehandlung bei der juvenilen idiopathischen Arthritis: Vergleich von Mono- und Kombinationstherapie mit synthetischen DMARDs. Z Rheumatol 2019;78:599-609. [DOI: 10.1007/s00393-019-0645-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Mehta P, Manson JJ. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? Front Immunol 2020;11:589. [PMID: 32318070 DOI: 10.3389/fimmu.2020.00589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Gerke AK. Treatment of Sarcoidosis: A Multidisciplinary Approach. Front Immunol 2020;11:545413. [PMID: 33329511 DOI: 10.3389/fimmu.2020.545413] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Parikh CR, Ponnampalam JK, Seligmann G, Coelewij L, Pineda-Torra I, Jury EC, Ciurtin C. Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. Ther Adv Musculoskelet Dis 2021;13:1759720X211002685. [PMID: 34188697 DOI: 10.1177/1759720X211002685] [Reference Citation Analysis]
93 Zhao WJ, Deng JH, Li CF. Research progress in drug therapy of juvenile idiopathic arthritis. World J Pediatr 2022. [PMID: 35364799 DOI: 10.1007/s12519-022-00530-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:295-300. [DOI: 10.1080/13543784.2018.1442433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
95 Kim JW, Jung JY, Suh CH. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther 2021;21:57-73. [PMID: 32808557 DOI: 10.1080/14712598.2020.1812575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Balsa A, Lula S, Marshall L, Szczypa P, Aikman L. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature. Expert Opin Biol Ther 2018;18:575-84. [PMID: 29533116 DOI: 10.1080/14712598.2018.1450385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
97 Cardiel MH, Carrillo S, Pérez M, Andrade L, Pacheco Tena C, Silveira LH, Limón L, Cerpa S, Gutiérrez Ureña S, Durán S, Irazoque Palazuelos F, Muñoz López S, Sicsik Ayala SA, Barile L, Ramos Sánchez MA, Grajeda Portes D, Portela M, Hernández Bedolla A, García-Figueroa JL, Montero M, Abud-Mendoza C, Martínez Martínez MU, Herrera van Ostdam D, Pascual-Ramos V, Merayo-Chalico J, Guzmán-Sánchez I, Pérez-Bastidas ME, Aguilar Arreola JE, López Rodríguez A, Reyes-Cordero G, Ricardez HA, Hernández Cabrera MF, Olvera-Soto G, Xibillé Friedmann D. Update of the Mexican College of Rheumatology Guidelines for the Pharmacological Treatment of Rheumatoid Arthritis, 2018. Reumatol Clin (Engl Ed) 2021;17:215-28. [PMID: 31103432 DOI: 10.1016/j.reuma.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021;73:924-39. [PMID: 34101387 DOI: 10.1002/acr.24596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
99 Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K. Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study. Biol Pharm Bull 2022;45:323-32. [PMID: 35228398 DOI: 10.1248/bpb.b21-00906] [Reference Citation Analysis]
100 Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Adv Ther 2020;37:4491-518. [PMID: 32910420 DOI: 10.1007/s12325-020-01472-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
101 Sun W, Wu Y, Zheng M, Yang Y, Liu Y, Wu C, Zhou Y, Zhang Y, Chen L, Li H. Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor. J Med Chem 2020;63:8146-56. [DOI: 10.1021/acs.jmedchem.0c00377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
102 Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Romita P, Raimondo A, Loconsole F, Fabbrocini G. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clin Drug Investig 2022. [PMID: 35633470 DOI: 10.1007/s40261-022-01163-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol 2021;147:1123-31. [PMID: 33832694 DOI: 10.1016/j.jaci.2021.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019;22:357-75. [PMID: 30809944 DOI: 10.1111/1756-185X.13513] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 15.3] [Reference Citation Analysis]
105 McKay KM, Apostolopoulos N, Chou B, Leveque TK, Van Gelder RN. Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series. Ocul Immunol Inflamm 2021;:1-5. [PMID: 34270383 DOI: 10.1080/09273948.2021.1936565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Sorensen PS. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs 2022. [PMID: 35590041 DOI: 10.1007/s40263-022-00920-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
108 Alegre-Sancho JJ, Juanola X, Rodríguez-Heredia JM, Manero J, Villa-Blanco I, Laiz A, Arteaga MJ, Cea-Calvo L, González CM. Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study. Medicine (Baltimore) 2021;100:e25223. [PMID: 33787605 DOI: 10.1097/MD.0000000000025223] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med 2021;10:4307. [PMID: 34640327 DOI: 10.3390/jcm10194307] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Li Y, Mai Y, Cao P, Wen X, Fan T, Wang X, Ruan G, Tang S, Ding C, Zhu Z. Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis. JCM 2022;11:3958. [DOI: 10.3390/jcm11143958] [Reference Citation Analysis]
111 Milidrag A, Gutić M, Rodić I, Pjevač A, Mladenović T, Miličić V, Ravić-nikolić A. Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab. Serbian Journal of Experimental and Clinical Research 2022;0. [DOI: 10.2478/sjecr-2022-0013] [Reference Citation Analysis]
112 Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 2021;17:81-97. [PMID: 33318665 DOI: 10.1038/s41584-020-00540-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
113 Kernstock R, Sperinde G, Finco D, Davis R, Montgomery D. Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody. AAPS J 2020;22:60. [PMID: 32185565 DOI: 10.1208/s12248-020-00440-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Carrasco-Triguero M, Dere RC, Milojic-Blair M, Saad OM, Nazzal D, Hong K, Kaur S. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. Bioanalysis 2019;11:1555-68. [PMID: 31208199 DOI: 10.4155/bio-2018-0259] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
115 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
116 Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases. Biologicals 2021;70:17-21. [PMID: 33676831 DOI: 10.1016/j.biologicals.2021.02.002] [Reference Citation Analysis]
117 Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755-66. [PMID: 30982883 DOI: 10.1093/rheumatology/kez087] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 41.5] [Reference Citation Analysis]
118 Esatoglu SN, Akkoc-Mustafayev FN, Ozguler Y, Ozbakır F, Nohut OK, Cevirgen D, Hamuryudan V, Hatemi I, Celik AF, Yazici H, Hatemi G. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. Front Immunol 2020;11:618973. [PMID: 33414791 DOI: 10.3389/fimmu.2020.618973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, Suarez-Almazor ME, Lyddiatt A, Kristensen LE, Bliddal H, Christensen R. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum 2019;48:958-66. [PMID: 30396592 DOI: 10.1016/j.semarthrit.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Tesar T, Golias P, Inotai A, Kawalec P, Wawruch M. The impact of implemented regulations on biosimilars in Slovakia. Health Policy and Technology 2019;8:408-13. [DOI: 10.1016/j.hlpt.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
121 Tanaka Y, Takahashi T, Sumi M, Hagino O, Van Hoogstraten H, Xu C, Kato N, Kameda H. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. Mod Rheumatol 2021:roab066. [PMID: 34915576 DOI: 10.1093/mr/roab066] [Reference Citation Analysis]
122 Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol Online J 2021;19:132. [PMID: 34419092 DOI: 10.1186/s12969-021-00630-1] [Reference Citation Analysis]
123 Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary Delivery of Biological Drugs. Pharmaceutics 2020;12:E1025. [PMID: 33114726 DOI: 10.3390/pharmaceutics12111025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
124 Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00614-5. [PMID: 34126262 DOI: 10.1016/j.cgh.2021.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
125 Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol 2018;45:279-86. [DOI: 10.1111/1346-8138.14096] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
126 Kim SH, Kim HR, Lee SH, Shin K, Kim HA, Min HK. Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis. Sci Rep 2021;11:21555. [PMID: 34732807 DOI: 10.1038/s41598-021-01132-6] [Reference Citation Analysis]
127 Botson JK, Baraf HSB, Keenan RT, Albert J, Masri KR, Peterson J, Yung C, Freyne B, Amin M, Abdellatif A, Soloman N, Edwards NL, Strand V. Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. Curr Rheumatol Rep 2022. [PMID: 35167037 DOI: 10.1007/s11926-022-01055-9] [Reference Citation Analysis]
128 Schick AJ 3rd, Lundin V, Low J, Peng K, Vandlen R, Wecksler AT. Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody. MAbs 2022;14:2028337. [PMID: 35072596 DOI: 10.1080/19420862.2022.2028337] [Reference Citation Analysis]
129 Mulleman D, Balsa A. Adalimumab concentration-based tapering strategy: as good as the recommended dosage. Ann Rheum Dis 2018;77:473-5. [PMID: 29306871 DOI: 10.1136/annrheumdis-2017-212376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
130 Bakulin IG, Skalinskaya MI, Maev IV, Skazyvaeva EV, Zhuravleva MS, Gaikovaya LB, Bakulina NV, Ermakov AI, Alekseenko ES, Ivanova KN, Solovev MV. Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management. Terapevticheskii arkhiv 2021;93:841-52. [DOI: 10.26442/00403660.2021.08.200982] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2021;73:1108-23. [PMID: 34101376 DOI: 10.1002/art.41752] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
132 Smits LJT, van Esch AAJ, Derikx LAAP, Boshuizen R, de Jong DJ, Drenth JPH, Hoentjen F. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Inflamm Bowel Dis 2019;25:172-9. [PMID: 29947795 DOI: 10.1093/ibd/izy227] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
133 Atalay S, Berends SE, Groenewoud HMM, Mathot RAA, Njoo DM, Mommers JM, Ossenkoppele PM, Koetsier MIA, Berends MA, de Vries A, van de Kerkhof PCM, den Broeder AA, de Jong EMGJ, van den Reek JMPA. Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. J Dermatolog Treat 2022;:1-5. [PMID: 35193441 DOI: 10.1080/09546634.2022.2043546] [Reference Citation Analysis]
134 Abad Hernández MÁ, Andreu JL, Balsa Criado A, Díaz-González F, Moreno Muelas JV, Queiro Silva R, Gómez-Reino JJ. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs. Reumatol Clin (Engl Ed) 2021;17:160-9. [PMID: 31054806 DOI: 10.1016/j.reuma.2019.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65-77. [PMID: 29797519 DOI: 10.1111/apt.14794] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 21.5] [Reference Citation Analysis]
136 Heron CE, Ghamrawi RI, Balogh EA, Feldman SR. Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. Am J Clin Dermatol 2021;22:221-31. [PMID: 33169802 DOI: 10.1007/s40257-020-00569-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study. Gastroenterology 2020;159:1592-1594.e1. [PMID: 32574622 DOI: 10.1053/j.gastro.2020.06.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
138 Hasan MM, Laws M, Jin P, Rahman KM. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates. Drug Discov Today 2021:S1359-6446(21)00409-8. [PMID: 34597756 DOI: 10.1016/j.drudis.2021.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
139 Gheorghe C, Svoboda P, Mateescu B. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis. J Drug Assess 2019;8:129-34. [PMID: 31259042 DOI: 10.1080/21556660.2019.1626735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
140 Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol 2021;14:179-210. [PMID: 33487042 DOI: 10.1080/17512433.2021.1878024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EK, Lazar-molnar E, Yeo KJ. Development and validation of a targeted affinity-enrichment and LC–MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clinica Chimica Acta 2018;483:308-14. [DOI: 10.1016/j.cca.2018.05.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
142 Lu JD, Milakovic M, Piguet V, Alavi A. Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review. Br J Dermatol 2021;184:555-7. [PMID: 33006769 DOI: 10.1111/bjd.19591] [Reference Citation Analysis]
143 Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol 2020;11:1301. [PMID: 32695107 DOI: 10.3389/fimmu.2020.01301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
144 Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. Biomed Res Int 2018;2018:9597362. [PMID: 29546072 DOI: 10.1155/2018/9597362] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
145 Nakae K, Masui S, Yonezawa A, Hashimoto M, Watanabe R, Murata K, Murakami K, Tanaka M, Ito H, Yokoyama K, Iwamoto N, Shimada T, Nakamura M, Denda M, Itohara K, Nakagawa S, Ikemi Y, Imai S, Nakagawa T, Hayakari M, Matsubara K. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data. PLoS One 2021;16:e0258601. [PMID: 34644354 DOI: 10.1371/journal.pone.0258601] [Reference Citation Analysis]
146 Keshvari MK, van Someren F, Sheikh S, Galea I. Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns. J Neuroimmunol 2021;361:577729. [PMID: 34624660 DOI: 10.1016/j.jneuroim.2021.577729] [Reference Citation Analysis]
147 Hoeppli RE, Pesenacker AM. Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases. Front Immunol 2019;10:46. [PMID: 30740105 DOI: 10.3389/fimmu.2019.00046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Matucci A, Nencini F, Vivarelli E, Bormioli S, Maggi E, Vultaggio A. Immunogenicity-unwanted immune responses to biological drugs - can we predict them? Expert Rev Clin Pharmacol 2021;14:47-53. [PMID: 32432941 DOI: 10.1080/17512433.2020.1772053] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Blauvelt A, Lacour J, Fowler J, Weinberg J, Gospodinov D, Schuck E, Jauch-lembach J, Balfour A, Leonardi C. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol 2018;179:623-31. [DOI: 10.1111/bjd.16890] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 16.5] [Reference Citation Analysis]